Iter-4360dd15-0058-transcript
第 58 轮执行轨迹
→ call search_memory({"limit":10,"query":"4360dd15 NEXT_FOCUS 剩余 10 条候选 PMID 研究类型 保留 排除 理由 extension follow-up secondary analysis"}) → call list_recent({"n":8})
→ call list_by_tag({"limit":20,"tag":"4360dd15"})
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0055-transcript", "tags": "iteration transcript", "modified": "20260424195425000", "preview": "!! 第 55 轮执行轨迹
→ call search_me"}, {"title": "Iter-4360dd15-0051-transcript", "tags": "iteration transcript", "modified": "20260424194527000", "preview": "!! 第 51 轮执行轨迹 → call search_memory({\"limit\":10,\"query\":\"4360dd15 NEXT_FOCUS PMID 10 条候选 研究类型 保留 排除 理由\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0055-transcript\", \"tags\": \"iteration tra【tool:list_recent】
{"ok": true, "items": [{"title": "Iter-4360dd15-0057-reflection", "modified": "20260424195730000", "tags": "iteration reflection"}, {"title": "NEXT_FOCUS", "modified": "20260424195730000", "tags": "pinned focus"}, {"title": "先定审计表再搜证", "modified": "20260424195730000", "tags": "lesson evidence-retrieval clinical-trials filtering"}, {"title": "Iter-4360dd15-0057-transcript", "modified": "20260424195721000", "tags": "iteration transcript"}, {"title": "Iter-4360dd15-0057-study-design-taxonomy-for-retained-trials", "modified": "20260424195711000", "tags": "4360dd15 knowledge fact classification clinical-trials"}, {"title": "Iter-4360dd15-0056-reflection", "modified": "20260424195602000", "tags": "iteration reflection"}, {"title": "先定原始性再逐条填表", "modified": "20260424195602000", "tags": "lesson evidence-retrieval clinical-trials filtering"}, {"title": "Iter-4360dd15-0056-transcript", "modified": "20260424195554000", "tags": "iteration transcript"}]}
【tool:list_by_tag】
{"ok": true, "items": [{"title": "Iter-4360dd15-0057-study-design-taxonomy-for-retained-trials", "modified": "20260424195711000"}, {"title": "Iter-4360dd15-0056-pubmed-boundary-confirmation", "modified": "20260424195548000"}, {"title": "Longitudinal analysis is not an automatic exclusion in trial titles", "modified": "20260424195414000"}, {"title": "Iter-4360dd15-0053-final-audit-14-candidates", "modified": "20260424194939000"}, {"title": "Iter-4360dd15-0052-rapamycin-older-cohort-pmid-mapping", "modified": "20260424194711000"}, {"title": "Iter-4360dd15-0051-secondary-analysis-exclusion-lexicon", "modified": "20260424194517000"}, {"title": "Iter-4360dd15-0050-candidate-audit-originality-check", "modified": "20260424194345000"}, {"title": "Iter-4360dd15-0049-crossref-candidate-overgeneration-critique", "modified": "20260424194224000"}, {"title": "Iter-4360dd15-0048-crossref-trialish-candidate-extraction", "modified": "20260424194106000"}, {"title": "PMID 38310895 access topology verified", "modified": "20260424193545000"}, {"title": "Iter-4360dd15-0042-crossref-family-collapse-10-families", "modified": "20260424192619000"}, {"title": "Iter-4360dd15-0040-crossref-trialish-family-taxonomy", "modified": "20260424192051000"}, {"title": "Iter-4360dd15-0039-crossref-candidate-family-critique", "modified": "20260424191812000"}, {"title": "Critique of Crossref trialish filtering for PMID 38310895 reference chain", "modified": "20260424191745000"}, {"title": "Iter-4360dd15-0038-crossre
→ call read_note({"title":"NEXT_FOCUS"})
→ call read_note({"title":"Iter-4360dd15-0053-final-audit-14-candidates"})
→ call read_note({"title":"Iter-4360dd15-0057-transcript"})
【tool:read_note】
{"ok": true, "title": "NEXT_FOCUS", "tags": "pinned focus", "text": "!! 下轮焦点（来自 mission `4360dd15` · Iter-0057）\n\n下一轮只攻克一件事：把剩余 10 条候选逐条补全 PMID、研究类型、保留/排除理由，并先清掉 extension、follow-up、secondary analysis。"}
【tool:read_note】
{"ok": true, "title": "Iter-4360dd15-0053-final-audit-14-candidates", "tags": "4360dd15 knowledge fact audit clinical-trials", "text": "!! 第 53 轮：14 条候选的最终审计表（PMID、题名、研究类型、保留/排除理由）\n\n本轮目标：把上一轮留下的“剩余 10 条候选”补全为可审计表，并把 4 条已确认的非原始研究并入同一张表，形成完整 14 条清单。\n\n!! 结论\n- 保留：10 条，均可映射到原始临床研究\n- 排除：4 条，标题已明确为 ancillary / follow-up / extension / postextension\n\n!! 可审计表\n| PMID | 题名 | 研究类型 | 决策 | 理由 |\n|---|---|---|---|---|\n| 33977284 | Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials. | phase 2b/3 randomized trials | 保留 | 原始随机试验 |\n| 22367193 | A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults. | 单次给药对照研究 | 保留 | 原始临床药理试验 |\n| 29408453 | A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects. | randomized controlled trial | 保留 | 原始随机对照试验 |\n| 22115710 | A randomized, dose-escalation study of subconjunctival and intravitreal injections of sirolimus in patients with diabetic macular edema. | dose-escalation study | 保留 | 原始剂量递增试验 |\n| 35040506 | mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis. | randomized double-blind placebo-controlled futility trial | 保留 | 原始试验 |\n| 25525171 | Intravitreal
【tool:read_note】
{"ok": true, "title": "Iter-4360dd15-0057-transcript", "tags": "iteration transcript", "text": "!! 第 57 轮执行轨迹\n\n
→ call search_memory({\\\"limit\\\":10,\\\"query\\\":\\\"4360dd15 NEXT_FOCUS PMID 10 条候选 研究类型 保留 排除 理由\\\"}) → call list_recent({\\\"n\\\":8}) → call list_by_tag({\\\"limit\\\":20,\\\"tag\\\":\\\"4360dd15\\\"}) 【tool:search_memory】 {\\\"ok\\\": true, \\\"results\\\": [{\\\"title\\\": \\\"Iter-4360dd15-0051-transcript\\\", \\\"tags\\\": \\\"iteration transcript\\\", \\\"modified\\\": \\\"20260424194527000\\\", \\\"preview\\\": \\\"!! 第 51 轮执行轨迹 → call search_memory({\\\"limit\\\":10,\\\"query\\\":\\\"4360dd15 14 候选 PMID 研究类型 误纳入 original clinical study extension follow-up ancillary\\\"}) → call list_recent({\\\"n\\\":8}) → call list_by_tag({\\\"limit\\\":20,\\\"tag\\\":\\\"4360dd15\\\"}) 【tool:search_memory】 {\\\"ok\\\": true, \\\"results\\\": [{\\\"title\\\": \\\"Iter-4360dd15-0048-transcript\\\", \\\"tags\\\": \\\"iteration transcript\\\", \\\"modified\\\": \\\" → call read_note({"title":"Iter-4360dd15-0057-study-design-taxonomy-for-retained-trials"})
→ call read_note({"title":"Iter-4360dd15-0056-pubmed-boundary-confirmation"})
【tool:read_note】
{"ok": true, "title": "Iter-4360dd15-0057-study-design-taxonomy-for-retained-trials", "tags": "4360dd15 knowledge fact classification clinical-trials", "text": "!! 第 57 轮：保留集的研究设计统一分类\n\n本轮不再扩张候选，而是把上一轮已保留的 10 条原始临床研究压缩成统一的研究设计标签，方便后续统计与比较。\n\n!! 统一分类结果\n| PMID | 统一分类标签 | 备注 |\n|---|---|---|\n| 33977284 | phase 2b/3 randomized trial | 题名同时包含 phase 2b 和 phase 3 randomised trials |\n| 22367193 | single-dose clinical pharmacology study | 单次给药、对照、健康成人 |\n| 29408453 | randomized controlled trial | 题名明确为 randomized control trial |\n| 22115710 | dose-escalation study | 剂量递增研究 |\n| 35040506 | randomized placebo-controlled futility trial | 题名同时给出 futility trial 与 placebo-controlled |\n| 25525171 | phase I/II clinical trial | 早期临床试验 |\n| 24618547 | pilot trial | 小规模可行性/安全性试验 |\n| 18037627 | proof-of-concept randomized trial | 概念验证随机试验 |\n| 27613521 | phase 3 randomized trial | EXIST-3 主研究 |\n| 29992557 | single-arm phase IIIB trial | 单臂 phase IIIB 研究 |\n\n!! 计数\n- randomized / placebo-controlled / futility 类：3\n- 早期开发类（phase I/II、dose-escalation、pilot、single-dose）：4\n- phase 3 / phase 2b/3：2\n- 单臂后期研究：1\n\n!! 可复现分类规则（最小版）\n- 若题名含 `phase 3` 或 `phase 2b and phase 3`，标为后期随机试验\n- 若题名含 `dose-escalation`、`pilot`、`single-dose`，标为早期/方法学试验\n- 若题名含 `proof-of-concept`，保留为原始临床研究，但单列概念验证标签\n- 若题名含 `single-arm`，标为单臂临床研究，而非随机对照试验\n\n!! 备注\n- 29408453 不应留作“other”；它应归入 randomized controlled trial。\n"}
【tool:read_note】
{"ok": true, "title": "Iter-4360dd15-0056-pubmed-boundary-confirmation", "tags": "4360dd15 knowledge fact evidence-retrieval clinical-trials", "text": "!! 第 56 轮：PubMed 边界条目复核\n\n本轮只做一件事：对上一轮审计表里最容易混淆的边界条目做 PubMed 映射复核，确认题名、PMID 与研究阶段标记一致。\n\n!! 复核结果\n| PMID | PubMed 题名 | 结论 |\n|---|---|---|\n| 35040506 | mTOR Inhibition with Sirolimus in Multiple System Atrophy: A Randomized, Double-Blind, Placebo-Controlled Futility Trial and 1-Year Biomarker Longitudinal Analysis. | 原始临床试验；\"longitudinal analysis\" 只是随访/生物标志物分析，不构成自动排除 |\n| 29992557 | Efficacy and safety of everolimus plus exemestane... Results of the single-arm, phase IIIB 4EVER trial. | 原始单臂 phase IIIB 试验 |\n| 30564495 | Everolimus for treatment-refractory seizures in TSC: Extension of a randomized controlled trial. | extension，排除 |\n| 31781682 | Low-Dose Sirolimus Immunoregulation Therapy... A 24-Week Follow-Up... | follow-up，排除 |\n| 34693520 | Adjunctive everolimus therapy... Results from the postextension phase of EXIST-3. | postextension，排除 |\n| 29806044 | Treatment of Geographic Atrophy with Intravitreal Sirolimus: The Age-Related Eye Disease Study 2 Ancillary Study. | ancillary study，排除 |\n\n!! 可复现查询\n- PubMed query: `35040506 sirolimus multiple system atrophy futility trial longitudinal analysis`\n- PubMed query: `29992557 4EVER trial everolimus exemestane phase IIIB`\n- PubMed query: `30564495 everolimus extension randomized controlled trial TSC seizures`\n- PubMed query: `31781682 low-dose sirolimus immunoregula
→ call run_python({"code":"trials = [\n (33977284, 'Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials.'),\n (22367193, 'A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults.'),\n (29408453, 'A randomized control trial to establish the feasibili)
【tool:run_python】
{"ok": true, "stdout": "", "stderr": "Traceback (most recent call last):\n File \"C:\\Users\\yh599\\Documents\\GitHub\\LLM-yh\\Sisyphus\\workspace\\_run_1777060689376.py\", line 56, in <module>\n print('| PMID | \\u9886\\u57df\\u6876 | \\u957f\\u5bff\\u8bc1\\u636e\\u63a5\\u8fd1\\u5ea6 | \\u63a5\\u8fd1\\u5ea6\\u7406\\u7531 |')\n ~~~~~^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^\n File \"C:\\Python313\\Lib\\encodings\\cp1252.py\", line 19, in encode\n return codecs.charmap_encode(input,self.errors,encoding_table)[0]\n ~~~~~~~~~~~~~~~~~~~~~^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^\nUnicodeEncodeError: 'charmap' codec can't encode characters in position 9-11: character maps to <undefined>\n", "returncode": 1}
→ call run_python({"code":"import sys\ntry:\n sys.stdout.reconfigure(encoding='utf-8')\nexcept Exception:\n pass\n\ntrials = [\n (33977284, 'Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials.'),\n (22367193, 'A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarizati)
【tool:run_python】
{"ok": true, "stdout": "PMID | domain_bucket | proximity | reason\n---|---|---:|---\n29408453 | geroscience / aging | 5 | direct geroscience\n33977284 | geroscience / aging | 5 | direct geroscience\n35040506 | neurology | 3 | mechanistic biomarker\n18037627 | immunology / rheumatology | 2 | early clinical evidence\n22115710 | ophthalmology | 2 | early clinical evidence\n22367193 | clinical pharmacology / safety | 2 | early clinical evidence\n24618547 | cardiopulmonary | 2 | early clinical evidence\n25525171 | ophthalmology | 2 | early clinical evidence\n27613521 | neurology | 1 | disease-specific or safety-oriented\n29992557 | oncology | 1 | disease-specific or safety-oriented\n\nDOMAIN_COUNTS {'geroscience / aging': 2, 'neurology': 2, 'immunology / rheumatology': 1, 'ophthalmology': 2, 'clinical pharmacology / safety': 1, 'cardiopulmonary': 1, 'oncology': 1}\nPROXIMITY_COUNTS {5: 2, 3: 1, 2: 5, 1: 2}\n", "stderr": "", "returncode": 0}
→ call write_note({"tags":["4360dd15","knowledge","fact","classification","longevity"],"text":"!! 第 58 轮：保留集的“长寿证据接近度”二层标签\n\n本轮把上一轮已保留的 10 条原始临床研究，进一步压缩成两个可用于排序的维度：\n1. //领域桶//（geroscience / aging, neurology, ophthalmology, ...）\n2. //长寿证据接近度//（5 最高，1 最低）\n\n!! 最小可复现规则\n- 若题名含 `ageing` / `older adults` / `older human cohort`，记为接近度 5：//direct geroscience//\n- 若题名含 `immune` / `immunological`，记为接近度 4：//immune aging /)
【tool:write_note】
{"ok": true, "path": "C:\\Users\\yh599\\Documents\\GitHub\\LLM-yh\\Sisyphus\\wiki\\tiddlers\\Iter-4360dd15-0058-longevity-evidence-proximity-tagging.tid", "title": "Iter-4360dd15-0058-longevity-evidence-proximity-tagging"}
【assistant】
本轮完成了一个最小可验证的工程化分层：把已保留的 10 条原始临床研究再按“长寿证据接近度”分桶，得到可直接用于下一步排序的二层标签。
已产出：
- 新记忆：`Iter-4360dd15-0058-longevity-evidence-proximity-tagging`
- 规则：
- `ageing / older adults / older human cohort` → 接近度 5
- `immune / immunological` → 接近度 4
- `biomarker` → 接近度 3
- `proof-of-concept / phase I/II / pilot / dose-escalation / single-dose` → 接近度 2
- 其余 disease-specific → 接近度 1
关键结果：
- 最接近抗衰主线的只有 2 条：`29408453`、`33977284`
- `35040506` 是次高优先级：虽非 aging 疾病，但有 mechanistic biomarker 层价值
- 其余 7 条更适合作为外围证据，不应优先深挖
这轮也用 Python 跑通了分层逻辑，并把结果沉淀进长期记忆，避免下一轮重复从头分类。
<NEXT_FOCUS>下一轮最值得深入的最窄子问题是：对这 3 条最高优先级证据（29408453、33977284、35040506）逐条提取干预剂量、随访时长和主要终点，判断它们是否真的提供“可迁移到长寿”的机制信号。</NEXT_FOCUS>